Mobia Medical Raises Full-Year Revenue Guidance Following 73% Q3 Growth
Mobia Medical (NASDAQ: MOBI) reported a significant increase in third-quarter revenue, totaling $15.6 million. This figure represents a substantial 73% year-over-year growth rate, driven largely by the expanding adoption of its Vivistim product. Following these strong quarterly results and robust business fundamentals, CEO Richard Foust announced that the company is raising its full-year revenue guidance. The company now expects total revenue for 2026 to fall within the range of $57.0 million to $57.5 million.
Tickers: $MOBI